<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35524620</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1723-8617</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>21</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>World psychiatry : official journal of the World Psychiatric Association (WPA)</Title>
          <ISOAbbreviation>World Psychiatry</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.</ArticleTitle>
        <Pagination>
          <StartPage>295</StartPage>
          <EndPage>307</EndPage>
          <MedlinePgn>295-307</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/wps.20972</ELocationID>
        <Abstract>
          <AbstractText>According to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia-spectrum disorders, but evidence-based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long-acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and online registers were searched to identify randomized controlled trials comparing LAIs or oral antipsychotics head-to-head or against placebo, published until June 2021. Relative risks and standardized mean differences were pooled using random-effects pairwise and network meta-analysis. The primary outcomes were relapse and dropout due to adverse events. We used the Cochrane Risk of Bias tool to assess study quality, and the CINeMA approach to assess the confidence of pooled estimates. Of 100 eligible trials, 92 (N=22,645) provided usable data for meta-analyses. Regarding relapse prevention, the vast majority of the 31 included treatments outperformed placebo. Compared to placebo, "high" confidence in the results was found for (in descending order of effect magnitude) amisulpride-oral (OS), olanzapine-OS, aripiprazole-LAI, olanzapine-LAI, aripiprazole-OS, paliperidone-OS, and ziprasidone-OS. "Moderate" confidence in the results was found for paliperidone-LAI 1-monthly, iloperidone-OS, fluphenazine-OS, brexpiprazole-OS, paliperidone-LAI 1-monthly, asenapine-OS, haloperidol-OS, quetiapine-OS, cariprazine-OS, and lurasidone-OS. Regarding tolerability, none of the antipsychotics was significantly worse than placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing "moderate" confidence levels. Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia-spectrum disorders, considering that both LAI and oral formulations of these antipsychotics are among the best-performing treatments and have the highest confidence of evidence for relapse prevention. This finding is of particular relevance for low- and middle-income countries and constrained-resource settings, where few medications may be selected. Results from this network meta-analysis can inform clinical guidelines and national and international drug regulation policies.</AbstractText>
          <CopyrightInformation>© 2022 World Psychiatric Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ostuzzi</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bertolini</LastName>
            <ForeName>Federico</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tedeschi</LastName>
            <ForeName>Federico</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vita</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brambilla</LastName>
            <ForeName>Paolo</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Del Fabro</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gastaldon</LastName>
            <ForeName>Chiara</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papola</LastName>
            <ForeName>Davide</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Purgato</LastName>
            <ForeName>Marianna</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nosari</LastName>
            <ForeName>Guido</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Del Giovane</LastName>
            <ForeName>Cinzia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Primary Health Care, University of Bern, Bern, Switzerland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Population Health Laboratory, University of Fribourg, Fribourg, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Correll</LastName>
            <ForeName>Christoph U</ForeName>
            <Initials>CU</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barbui</LastName>
            <ForeName>Corrado</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>World Psychiatry</MedlineTA>
        <NlmUniqueID>101189643</NlmUniqueID>
        <ISSNLinking>1723-8617</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Relapse prevention</Keyword>
        <Keyword MajorTopicYN="N">aripiprazole</Keyword>
        <Keyword MajorTopicYN="N">long-acting antipsychotics</Keyword>
        <Keyword MajorTopicYN="N">maintenance treatment</Keyword>
        <Keyword MajorTopicYN="N">olanzapine</Keyword>
        <Keyword MajorTopicYN="N">oral antipsychotics</Keyword>
        <Keyword MajorTopicYN="N">paliperidone</Keyword>
        <Keyword MajorTopicYN="N">schizophrenia-spectrum disorders</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35524620</ArticleId>
        <ArticleId IdType="pmc">PMC9077618</ArticleId>
        <ArticleId IdType="doi">10.1002/wps.20972</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet
2016;388:86‐97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4940219</ArticleId>
            <ArticleId IdType="pubmed">26777917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McEvoy JP. The importance of early treatment of schizophrenia. Behav Healthc
2007;27:40‐3.</Citation>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Rubio JM, Kane JM. What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
World Psychiatry
2018;17:149‐60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5980517</ArticleId>
            <ArticleId IdType="pubmed">29856543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fountoulakis KN, Moeller HJ, Kasper S et al. The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr
2021;26:562‐86.</Citation>
        </Reference>
        <Reference>
          <Citation>
Huhn M, Nikolakopoulou A, Schneider‐Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‐episode schizophrenia: a systematic review and network meta‐analysis. Lancet
2019;394:939‐51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6891890</ArticleId>
            <ArticleId IdType="pubmed">31303314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao YJ, Lin L, Teng M et al. Long‐term antipsychotic treatment in schizophrenia: systematic review and network meta‐analysis of randomised controlled trials. BJPsych Open
2016;2:59‐66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4995551</ArticleId>
            <ArticleId IdType="pubmed">27703755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Hagi K, Nitta M et al. Long‐term effectiveness of oral second‐generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta‐analysis of direct head‐to‐head comparisons. World Psychiatry
2019;18:208‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6502423</ArticleId>
            <ArticleId IdType="pubmed">31059621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Agarwal V, Kishi T et al. Relapse prevention in schizophrenia: a systematic review and meta‐analysis of second‐generation antipsychotics versus first‐generation antipsychotics. Mol Psychiatry
2013;18:53‐66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3320691</ArticleId>
            <ArticleId IdType="pubmed">22124274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ceraso A, Lin JJ, Schneider‐Thoma J et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev
2020;8:CD008016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32840872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ostuzzi G, Bertolini F, Del Giovane C et al. Maintenance treatment with long‐acting injectable antipsychotics for people with nonaffective psychoses: a network meta‐analysis. Am J Psychiatry
2021;178:424‐36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33596679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solmi M, Murru A, Pacchiarotti I et al. Safety, tolerability, and risks associated with first‐ and second‐generation antipsychotics: a state‐of‐the‐art clinical review. Ther Clin Risk Manag
2017;13:757‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5499790</ArticleId>
            <ArticleId IdType="pubmed">28721057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Detraux J, De Lepeleire J et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry
2015;14:119‐36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4471960</ArticleId>
            <ArticleId IdType="pubmed">26043321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gaebel W, Stricker J, Riesbeck M. The long‐term antipsychotic treatment of schizophrenia: a selective review of clinical guidelines and clinical case examples. Schizophr Res
2020;225:4‐14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31806527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Patel C, Benson C et al. A systematic literature review of schizophrenia clinical practice guidelines: recommendations for the acute and maintenance management with antipsychotics. NPJ Schizophr
2022;8:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8873492</ArticleId>
            <ArticleId IdType="pubmed">35210430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nosé M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes?
A systematic review. Psychol Med
2003;33:1149‐60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14580069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Marder SR. Overview of partial compliance. J Clin Psychiatry
2003;64(Suppl. 16):3‐9.</Citation>
        </Reference>
        <Reference>
          <Citation>
Chen EY, Hui CL, Dunn EL et al. A prospective 3‐year longitudinal study of cognitive predictors of relapse in first‐episode schizophrenic patients. Schizophr Res
2005;77:99‐104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16005389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kane JM, Kishimoto T, Correll CU. Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry
2013;12:216‐26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3799245</ArticleId>
            <ArticleId IdType="pubmed">24096780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci
2014;16:505‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4336920</ArticleId>
            <ArticleId IdType="pubmed">25733955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rubio JM, Taipale H, Tanskanen A et al. Long‐term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull
2021;47:1611‐20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8530382</ArticleId>
            <ArticleId IdType="pubmed">34129663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Hagi K, Kurokawa S et al. Long‐acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta‐analysis of randomised, cohort, and pre‐post studies. Lancet Psychiatry
2021;8:387‐404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33862018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taipale H, Mehtala J, Tanskanen A et al. Comparative effectiveness of anti­psychotic drugs for rehospitalization in schizophrenia – a nationwide study with 20‐year follow‐up. Schizophr Bull
2018;44:1381‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6192491</ArticleId>
            <ArticleId IdType="pubmed">29272458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Huhn M, Nikolakopoulou A, Schneider‐Thoma J et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‐episode schizophrenia: a systematic review and network meta‐analysis. Lancet
2019;394:939‐51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6891890</ArticleId>
            <ArticleId IdType="pubmed">31303314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta‐analyses of health care interventions: checklist and explanations. Ann Intern Med
2015;162:777‐84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26030634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leucht S, Kane JM, Kissling W et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry
2005;187:366‐71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16199797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leucht S, Kane JM, Kissling W et al. What does the PANSS mean?
Schizophr Res
2005;79:231‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15982856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miura T, Noma H, Furukawa TA et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta‐analysis. Lancet Psychiatry
2014;1:351‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26360999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Higgins JPT, Thomas J, Chandler J et al (eds). Cochrane handbook for systematic reviews of interventions. 2nd ed.
Chichester: Wiley, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>
Higgins JPT, Thomas J, Chandler J et al (eds). Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>
Wang D, Gopal S, Baker S et al. Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophr
2018;4:10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6010453</ArticleId>
            <ArticleId IdType="pubmed">29925851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leucht S, Rothe P, Davis JM et al. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol
2013;23:956‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23433639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Kishimoto T, Nielsen J et al. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther
2011;33:B16‐39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3298768</ArticleId>
            <ArticleId IdType="pubmed">22177377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Furukawa TA, Cipriani A, Barbui C et al. Imputing response rates from means and standard deviations in meta‐analyses. Int Clin Psychopharmacol
2005;20:49‐52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15602117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
R Core Team. R
: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>
StataCorp. Stata statistical software: release 17. College Station: StataCorp LLC, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>
Gardner DM, Murphy AL, O'Donnell H et al. International consensus study of antipsychotic dosing. Am J Psychiatry
2010;167:686‐93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20360319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leucht S, Samara M, Heres S et al. Dose equivalents for second‐generation antipsychotics: the minimum effective dose method. Schizophr Bull
2014;40:314‐26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3932104</ArticleId>
            <ArticleId IdType="pubmed">24493852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
European Medicines Agency
. EMA/737723/2013 ‐ Assessment report ABILIFY MAINTENA. London: European Medicines Agency, 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>
Haddad P, Lambert T, Lauriello J (eds). Antipsychotic long‐acting injections, 2nd ed.
Oxford: Oxford University Press, 2016.</Citation>
        </Reference>
        <Reference>
          <Citation>
Altman DG, Bland JM. Detecting skewness from summary information. BMJ
1996;313:1200.</Citation>
        </Reference>
        <Reference>
          <Citation>
Furukawa TA, Barbui C, Cipriani A et al. Imputing missing standard deviations in meta‐analyses can provide accurate results. J Clin Epidemiol
2006;59:7‐10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16360555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med
2004;23:3105‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15449338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shim SR, Kim SJ, Lee J et al. Network meta‐analysis: application and practice using R software. Epidemiol Health
2019;41:e2019013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6635665</ArticleId>
            <ArticleId IdType="pubmed">30999733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta‐analyses of continuous outcome data. J Clin Epidemiol
2015;68:52‐60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4270451</ArticleId>
            <ArticleId IdType="pubmed">25304503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nosè M, Tansella M, Thornicroft G et al. Is the Defined Daily Dose system a reliable tool for standardizing antipsychotic dosages?
Int Clin Psychopharmacol
2008;23:287‐90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18703938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cipriani A, Higgins JP, Geddes JR et al. Conceptual and technical challenges in network meta‐analysis. Ann Intern Med
2013;159:130‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23856683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bucher HC, Guyatt GH, Griffith LE et al. The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. J Clin Epidemiol
1997;50:683‐91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9250266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shih MC, Tu YK. An evidence‐splitting approach to evaluation of direct‐indirect evidence inconsistency in network meta‐analysis. Res Synth Methods
2021;12:226‐38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33543575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Higgins JP, Jackson D, Barrett JK et al. Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies. Res Synth Methods
2012;3:98‐110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4433772</ArticleId>
            <ArticleId IdType="pubmed">26062084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Veroniki AA, Vasiliadis HS, Higgins JP et al. Evaluation of inconsistency in networks of interventions. Int J Epidemiol
2013;42:332‐45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5411010</ArticleId>
            <ArticleId IdType="pubmed">23508418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jackson D, Barrett JK, Rice S et al. A design‐by‐treatment interaction model for network meta‐analysis with random inconsistency effects. Stat Med
2014;33:3639‐54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4285290</ArticleId>
            <ArticleId IdType="pubmed">24777711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rücker G, Krahn U, König J et al. netmeta: network meta‐analysis using frequentist methods. https://cran.r‐project.org/web/packages/netmeta/netmeta.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>
Van Valkenhoef G, Kuiper J. gemtc: network meta‐analysis using Bayesian methods. https://rdrr.io/cran/gemtc.</Citation>
        </Reference>
        <Reference>
          <Citation>
Egger M, Davey Smith G, Schneider M et al. Bias in meta‐analysis detected by a simple, graphical test. BMJ
1997;315:629‐34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2127453</ArticleId>
            <ArticleId IdType="pubmed">9310563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Salanti G, Del Giovane C, Chaimani A et al. Evaluating the quality of evidence from a network meta‐analysis. PLoS One
2014;9:e99682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4084629</ArticleId>
            <ArticleId IdType="pubmed">24992266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al. CINeMA: an approach for assessing confidence in the results of a network meta‐analysis. PLoS Med
2020;17:e1003082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7122720</ArticleId>
            <ArticleId IdType="pubmed">32243458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alvarez E, Ciudad A, Olivares JM et al. A randomized, 1‐year follow‐up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol
2006;26:238‐49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16702888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Arato M, O'Connor R, Meltzer HY. A 1‐year, double‐blind, placebo‐controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol
2002;17:207‐15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12177583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bai YM, Yu SC, Chen JY et al. Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. Int Clin Psychopharmacol
2005;20:79‐85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15729082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Beasley CM, Sutton VK, Hamilton SH et al. A double‐blind, randomized, placebo‐controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol
2003;23:582‐94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14624189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berwaerts J, Liu Y, Gopal S et al. Efficacy and safety of the 3‐month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry
2015;72:830‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25820612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bozzatello P, Bellino S, Mancini I et al. Effects on satisfaction and service engagement of paliperidone palmitate compared with oral paliperidone in patients with schizophrenia: an open label randomized controlled trial. Clin Drug Investig
2019;39:169‐78.</Citation>
        </Reference>
        <Reference>
          <Citation>
Buchanan RW, Panagides J, Zhao J et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psycho­pharmacol
2012;32:36‐45.</Citation>
        </Reference>
        <Reference>
          <Citation>
Charalampous KD, Thornby J, Ford BK et al. Penfluridol versus oral fluphenazine in the maintenance treatment of chronic schizophrenics. Curr Ther Res Clin Exp
1977;21:215‐23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">403056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chen EY, Hui CL, Lam MM et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ
2010;341:c4024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2924475</ArticleId>
            <ArticleId IdType="pubmed">20724402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chouinard G, Annable L, Campbell W et al. A double‐blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacol Bull
1984;20:108‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6371871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long‐acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol
2005;15:111‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15572280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Citrome L, Cucchiaro J, Sarma K et al. Long‐term safety and tolerability of lurasidone in schizophrenia: a 12‐month, double‐blind, active‐controlled study. Int Clin Psychopharmacol
2012;27:165‐76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22395527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Crespo‐Facorro B, Rodríguez‐Sánchez JM, Pérez‐Iglesias R et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first‐episode psychosis: a randomized, controlled 1‐year follow‐up comparison. J Clin Psychiatry
2009;70:717‐29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19389335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med
2002;346:16‐22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11777998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Daniel DG, Wozniak P, Mack RJ et al. Long‐term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull
1998;34:61‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9564200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Hert M, Mittoux A, He Y et al. Metabolic parameters in the short‐ and long‐term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci
2011;261:231‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20820795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Deberdt W, Lipkovich I, Heinloth AN et al. Double‐blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder. Ther Clin Risk Manag
2008;4:713‐20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2621385</ArticleId>
            <ArticleId IdType="pubmed">19209252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giudice JD, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics
1975;16:32‐6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1178806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dencker SJ, Frankenberg K, Malm U et al. A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial. Acta Psychiatr Scand
1973;49(Suppl. 241):101‐18.</Citation>
        </Reference>
        <Reference>
          <Citation>
Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double‐blind study of clopenthixol decanoate and flupenthixol palmitate. Acta Psychiatr Scand
1980;61(Suppl. 279):10‐28.</Citation>
        </Reference>
        <Reference>
          <Citation>
Detke HC, Weiden PJ, Llorca PM et al. Comparison of olanzapine long‐acting injection and oral olanzapine: a 2‐year, randomized, open‐label study in outpatients with schizophrenia. J Clin Psychopharmacol
2014;34:426‐34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24781441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Durgam S, Earley W, Li R et al. Long‐term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double‐blind, placebo‐controlled trial. Schizophr Res
2016;176:264‐71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27427558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fleischhacker WW, Baker RA, Eramo A et al. Effects of aripiprazole once‐monthly on symptoms and functioning of patients with an acute episode of schizophrenia stratified by age. Neuropsychopharmacology
2014;39:S375.</Citation>
        </Reference>
        <Reference>
          <Citation>
Freeman LS, Alson E. Prolonged withdrawal of chlorpromazine in chronic patients. Dis Nerv Syst
1962;23:522‐5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13894892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fu DJ, Turkoz I, Simonson RB et al. Paliperidone palmitate once‐monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double‐blind, randomized study of schizoaffective disorder. J Clin Psychiatry
2015;76:253‐62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25562685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gaebel W, Schreiner A, Bergmans P et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long‐acting injectable vs quetiapine: results of a long‐term, open‐label, randomized clinical trial. Neuropsychopharmacology
2010;35:2367‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3055334</ArticleId>
            <ArticleId IdType="pubmed">20686456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gallant DM, Mielke DH, Spirtes MA et al. Penfluridol: an efficacious long‐acting oral antipsychotic compound. Am J Psychiatry
1974;131:699‐702.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4597305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gerlach J, Kramp P, Kristjansen P et al. Peroral and parenteral administration of long‐acting neuroleptics: a double‐blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychiatr Scand
1975;52:132‐44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1096541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gitlin M, Nuechterlein K, Subotnik KL et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent‐onset schizophrenia. Am J Psychiatry
2001;158:1835‐42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11691689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Good WW, Sterling M, Holtzman WH. Termination of chlorpromazine with schizophrenic patients. Am J Psychiatry
1958;115:443‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13583246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goldberg JF, Ng‐Mak D, Siu C et al. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post‐hoc analysis of a randomized, placebo‐controlled study with longer‐term extension. CNS Spectr
2017;22:220‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28264739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Green AI, Brunette MF, Dawson R et al. Long‐acting injectable vs oral risperidone for schizophrenia and co‐occurring alcohol use disorder: a ran­domized trial. J Clin Psychiatry
2015;76:1359‐65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26302441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gross HS. A double‐blind comparison of once‐a‐day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Curr Ther Res Clin Exp
1974;16:696‐705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4210459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hershon HI, Kennedy PF, McGuire RJ. Persistence of extra‐pyramidal disorders and psychiatric relapse after withdrawal of long‐term phenothiazine therapy. Br J Psychiatry
1972;120:41‐50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4557435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hirsch SR, Kissling W, Bäuml J et al. A 28‐week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry
2002;63:516‐23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12088164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hirsch SR, Gaind R, Rohde PD et al. Outpatient maintenance of chronic schizophrenic patients with long‐acting fluphenazine: double‐blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J
1973;1:633‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1588639</ArticleId>
            <ArticleId IdType="pubmed">4571196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hirsch SR KA, Okasha MS, Salih MA. Maintenance therapy in out‐patient schizophrenics: a report of a double‐blind trial comparison of fluphenazine decanoate and flupenthixol decanoate. Br J Psychiatry
1978;133:370‐1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Arch Gen Psychiatry
1973;28:54‐64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4345664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hogarty GE, Schooler NR, Ulrich R et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two‐year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry
1979;36:1283‐94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">227340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hollister LE, Erickson GV, Motzenbecker FP. Trifluoperazine in chronic psychiatric patients. J Clin Exp Psychopathol Q Rev Psychiatry Neurol
1960;21:15‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14402702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hough D, Gopal S, Vijapurkar U et al. Paliperidone palmitate maintenance treatment in delaying the time‐to‐relapse in patients with schizophrenia: a randomized, double‐blind, placebo‐controlled study. Schizophr Res
2010;116:107‐17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19959339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ishigooka J, Nakamura J, Fujii Y et al. Efficacy and safety of aripiprazole once‐monthly in Asian patients with schizophrenia: a multicenter, randomized, double‐blind, non‐inferiority study versus oral aripiprazole. Schizophr Res
2015;161:421‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25556976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jolley AG, Hirsch SR, Morrison E et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ
1990;301:837‐42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1663999</ArticleId>
            <ArticleId IdType="pubmed">2282421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kamijima K, Higuchi T, Ishigooka J et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double‐blind, placebo‐controlled study (ADMIRE study). J Affect Disord
2013;151:899‐905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24074484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kane JM. Ziprasidone in schizophrenia: from acute treatment to long‐term management. J Clin Psychiatry
2003;64(Suppl. 19):3‐5.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kane JM, Mackle M, Snow‐Adami L et al. Double‐blind, placebo‐controlled trial of asenapine in prevention of relapse after long‐term treatment of schizophrenia. Int J Neuropsychopharmacol
2010;13:223.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kane JM, Mackle M, Snow‐Adami L et al. A randomized placebo‐controlled trial of asenapine for the prevention of relapse of schizophrenia after long‐term treatment. J Clin Psychiatry
2011;72:349‐55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21367356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52‐week, multicenter, randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry
2012;73:617‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22697189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaneno S, Okuma T, Yamashita et al. A double‐blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. Clinical
Evaluation
1991;19:15‐45.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kelly HB, Freeman HL, Banning B et al. Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. Int Pharmacopsychiatry
1977;12:54‐64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">406212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kern RS, Green MF, Cornblatt BA et al. The neurocognitive effects of aripiprazole: an open‐label comparison with olanzapine. Psychopharmacology
2006;187:312‐20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16810506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kissling W, Möller HJ, Walter K et al. Double‐blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side‐effects, dosage and serum levels during a six months' treatment for relapse prevention. Pharmacopsychiatry
1985;18:240‐5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4011672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kramer M, Simpson G, Maciulis V et al. Paliperidone extended‐release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double‐blind, placebo‐controlled study. J Clin Psychopharmacol
2007;27:6‐14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17224706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suresh Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian J Psychiatry
2016;58:311‐6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5100124</ArticleId>
            <ArticleId IdType="pubmed">28066010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laties AM, Flach AJ, Baldycheva I et al. Cataractogenic potential of quetiapine versus risperidone in the long‐term treatment of patients with schizophrenia or schizoaffective disorder: a randomized, open‐label, ophthalmologist‐masked, flexible‐dose, non‐inferiority trial. J Psychopharmacol
2015;29:69‐79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25315830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lecrubier Y, Quintin P, Bouhassira M et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6‐month double‐blind controlled clinical trial. Acta Psychiatr Scand
2006;114:319‐27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17022791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Leong OK, Wong KE, Tay WK et al. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Med J
1989;30:436‐40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2575796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lundin L, Dencker SJ, Malm U. Community‐based rehabilitation of schizophrenia. Nord J Psychiatry
1992;46:121‐7.</Citation>
        </Reference>
        <Reference>
          <Citation>
Macfadden W, Ma Y‐W, Haskins JT et al. A prospective study comparing the long‐term effectiveness of injectable risperidone long‐acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry
2010;7:23‐31.</Citation>
        </Reference>
        <Reference>
          <Citation>
Marder SR, Glynn SM, Wirshing WC et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2‐year outcomes. Am J Psychiatry
2003;160:1405‐12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12900301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McEvoy JP, Byerly M, Hamer RM et al. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA
2014;311:1978‐87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4101890</ArticleId>
            <ArticleId IdType="pubmed">24846035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Naber D, Peuskens J, Schwarzmann N et al. Subjective well‐being in schizophrenia: a randomised controlled open‐label 12‐month non‐inferiority study comparing quetiapine XR with risperidone (RECOVER). Eur Neuropsychopharmacol
2013;23:1257‐69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23953270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Németh G, Laszlovszky I, Czobor P et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double‐blind, controlled trial. Lancet
2017;389:1103‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28185672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nielsen J, Matz J, Mittoux A et al. Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double‐blind study in patients with schizophrenia. Eur Neuropsychopharmacol
2015;25:303‐11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25583364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Noordsy DL, Glynn SM, Sugar CA et al. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: eighteen‐month outcomes. J Psychiatr Res
2017;95:299‐307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5653420</ArticleId>
            <ArticleId IdType="pubmed">28942217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Odejide OA, Aderounmu AF. Double‐blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. J Clin Psychiatry
1982;43:195‐6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7076630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ota KY, Kurland AA. A double‐blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia. J Clin Pharmacol New Drugs
1973;13:99‐110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4568299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Peuskens J, Trivedi J, Malyarov S et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo‐controlled trial in clinically stable patients. Psychiatry
2007;4:34‐50.</Citation>
        </Reference>
        <Reference>
          <Citation>
Pigott TA, Carson WH, Saha AR et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo‐controlled 26‐week study. J Clin Psychiatry
2003;64:1048‐56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14628980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pinto R, Bannerjee A, Ghosh N. A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatr Scand
1979;60: 313‐22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">390972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Potkin SG, Loze JY, Forray C et al. Multidimensional assessment of functional outcomes in schizophrenia: results from QUALIFY, a head‐to‐head trial of aripiprazole once‐monthly and paliperidone palmitate. Int J Neuropsycho­pharmacol
2017;20:40‐9.</Citation>
        </Reference>
        <Reference>
          <Citation>
Potkin SG, Weiden PJ, Loebel AD et al. Remission in schizophrenia: 196‐week, double‐blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol
2009;12:1233‐48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19419595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prien RF, Levine J, Cole JO. High dose trifluoperazine therapy in chronic schiz­ophrenia. Am J Psychiatry
1969;126:305‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4895559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Purdon SE, Jones BD, Stip E et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry
2000;57:249‐58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10711911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Quitkin F, Rifkin A, Kane J et al. Long‐acting oral vs injectable antipsychotic drugs in schizophrenics: a one‐year double‐blind comparison in multiple episode schizophrenics. Arch Gen Psychiatry
1978;35:889‐92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">98127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rifkin A, Quitkin F, Klein DF. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data. Arch Gen Psychiatry
1977;34:1215‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">199129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ritchie CW, Chiu E, Harrigan S et al. The impact upon extra‐pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry
2003;18:432‐40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12766921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rui Q, Wang Y, Liang S et al. Relapse prevention study of paliperidone extended‐release tablets in Chinese patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
2014;53:45‐53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24576532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Savitz AJ, Xu H, Gopal S et al. Efficacy and safety of paliperidone palmitate 3‐month formulation for patients with schizophrenia: a randomized, multicenter, double‐blind, noninferiority study. Int J Neuropsychopharmacol
2016;19:pyw018.</Citation>
        </Reference>
        <Reference>
          <Citation>
Schooler NR, Levine J, Severe JB et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry
1980;37:16‐24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7352836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schneider SJ, Kirby EJ, Itil TM. Clinical blood chemistry values and long acting phenothiazines. Pharmacopsychiatria
1981;14:107‐14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6114503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schlosberg A SM. A comparative controlled study of two long‐acting phenothiazines: pipothiazine palmitate and fluphenazine decanoate. Curr Ther Res
1978;23:642‐54.</Citation>
        </Reference>
        <Reference>
          <Citation>
Schreiner A, Niehaus D, Shuriquie NA et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol
2012;32:449‐57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22722501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. J Nerv Ment Dis
1972;154:31‐42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4550211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shrivastava A, Gopa S. Comparative study of risperidone and haloperidol on clinical and psychosocial parameters in treatment of schizophrenia: a randomised open trial. Indian J Psychiatry
2000;42: 52‐6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2957003</ArticleId>
            <ArticleId IdType="pubmed">21407908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Song Y.
A double‐blind control study on the effect of pipotiazine palmitate and fluphenazine decanoate in the treatment of schizophrenia. Chinese J Neurol Psychiatry
1993;26:137‐40.</Citation>
        </Reference>
        <Reference>
          <Citation>
Speller JC, Barnes TR, Curson DA et al. One‐year, low‐dose neuroleptic study of in‐patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry
1997;171:564‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9519098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Subotnik KL, Casaus LR, Ventura J et al. Long‐acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry
2015;72:822‐9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5065351</ArticleId>
            <ArticleId IdType="pubmed">26107752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tandon R, Cucchiaro J, Phillips D et al. A double‐blind, placebo‐controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol
2016;30:69‐77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4717319</ArticleId>
            <ArticleId IdType="pubmed">26645209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Voruganti LP, Awad AG, Parker G et al. Cognition, functioning and quality of life in schizophrenia treatment: results of a one‐year randomized controlled trial of olanzapine and quetiapine. Schizophr Res
2007;96:146‐55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17728106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wani RA, Dar MA, Chandel RK et al. Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double‐blind, randomized, open‐label study. Neuropsychiatr Dis Treat
2015;11:685‐93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4364593</ArticleId>
            <ArticleId IdType="pubmed">25792838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weiden PJ, Manning R, Wolfgang CD et al. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE study. CNS Drugs
2016;30:735‐47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4982888</ArticleId>
            <ArticleId IdType="pubmed">27379654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wistedt B, Koskinen T, Thelander S et al. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double‐blind multicentre study. Acta Psychiatr Scand
1991;84:14‐21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1681680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wistedt BP. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. Int Clin Psychopharmacol
1986;1(Suppl. 1):15‐23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3549878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woggon B, Dick P, Fleischhauer HJ et al. Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double‐blind trial. Int Pharmacopsychiatry
1977;12:193‐209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lilly Ely. NCT00190749. Safety study of olanzapine and a comparator in patients with schizophrenia and schizoaffective disorder.
https://clinicaltrials.gov.</Citation>
        </Reference>
        <Reference>
          <Citation>
Janssen Ltd. NCT00236379
. A study of the effects of risperidone and olanzapine on blood glucose (sugar) in patients with schizophrenia or schizoaffective disorder. https://clinicaltrials.gov.</Citation>
        </Reference>
        <Reference>
          <Citation>
Janssen Ltd. NCT00253110. A comparison of risperidone with haloperidol in patients with schizophrenia and schizoaffective disorder.
https://clinicaltrials.gov.</Citation>
        </Reference>
        <Reference>
          <Citation>
Janssen Korea Ltd. NCT00992407
. An efficacy and safety study of long acting injectable risperidone and oral risperidone in participants with schizophrenia or schizoaffective disorder. https://clinicaltrials.gov.</Citation>
        </Reference>
        <Reference>
          <Citation>
Tiihonen J, Mittendorfer‐Rutz E, Majak M et al. Real‐world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry
2017;74:686‐93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5710250</ArticleId>
            <ArticleId IdType="pubmed">28593216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Nitta M, Borenstein M et al. Long‐acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta‐analysis of mirror‐image studies. J Clin Psychiatry
2013;74:957‐65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24229745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tiihonen J, Taipale H, Mehtälä J et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry
2019;76:499‐507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6495354</ArticleId>
            <ArticleId IdType="pubmed">30785608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Hagi K, Nitta M et al. Effectiveness of long‐acting injectable vs oral antipsychotics in patients with schizophrenia: a meta‐analysis of prospective and retrospective cohort studies. Schizophr Bull
2018;44:603‐19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5890463</ArticleId>
            <ArticleId IdType="pubmed">29868849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kishimoto T, Robenzadeh A, Leucht C et al. Long‐acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta‐analysis of randomized trials. Schizophr Bull
2014;40:192‐213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3885289</ArticleId>
            <ArticleId IdType="pubmed">23256986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Haddad PM, Kishimoto T, Correll CU et al. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry
2015;28:216‐21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25785710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ostuzzi G, Barbui C. Comparative effectiveness of long‐acting antipsychotics: issues and challenges from a pragmatic randomised study. Epidemiol Psychiatr Sci
2016;25:21‐3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6998676</ArticleId>
            <ArticleId IdType="pubmed">26515607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ostuzzi G, Papola D, Gastaldon C et al. New EMA report on paliperidone 3‐month injections: taking clinical and policy decisions without an adequate evidence base. Epidemiol Psychiatr Sci
2017;26:231‐3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6998643</ArticleId>
            <ArticleId IdType="pubmed">28004623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry
2017;16:163‐80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5428179</ArticleId>
            <ArticleId IdType="pubmed">28498599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solmi M, Tiihonen J, Lähteenvuo M et al. Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schiz­ophrenia: results from a nationwide, within‐subject design study. Schizophr Bull
2022;48:166‐75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8781351</ArticleId>
            <ArticleId IdType="pubmed">34286338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Taipale H, Tanskanen A, Mehtälä J et al. 20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry
2020;19:61‐8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6953552</ArticleId>
            <ArticleId IdType="pubmed">31922669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med
2012;9:e1001189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3308934</ArticleId>
            <ArticleId IdType="pubmed">22448149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
American Psychiatric Association
. Practice guideline for the treatment of patients with schizophrenia. Washington: American Psychiatric Association, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>
World Health Organization. mhGAP intervention guide for mental, neurological and substance use disorders in non‐specialized health settings: mental health Gap Action Programme (mhGAP) – version 2.0. Geneva: World Health Organization, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>
National Institute for Health and Care Excellence
. Psychosis and schizophrenia in adults. Treatment and management. National Clinical Guideline Number 178. London: National Institute for Health and Care Excellence, 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>
Burrone E, Gotham D, Gray A et al. Patent pooling to increase access to essential medicines. Bull World Health Organ
2019;97:575‐7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6653814</ArticleId>
            <ArticleId IdType="pubmed">31384076</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
